The impact of pharmaceutical ipr and national health insurance pricing policy on pharmacoeconomic development of taiwan
- At: 2007 FIP Congress in Beijing (China)
- Type: Poster
- By: WANG, Hui-po (Chang Gung Univ College of Medicine, Tao-yuan, China Taiwan)
- Co-author(s): Tseng, Y. Jane (National Taiwan University, TAIPEI, China Taiwan)
Lin, Yuling (Chang Gung Univ/College of Medicine, TAO-YUAN, China Taiwan)
Objective: Drugs paid by National Health Insurance Plan-Taiwan (NHI) are categorized as branded pharmaceuticals with IPR, branded pharmaceuticals with expired IPR, bioequivalent generics (BE) and generics. We evaluated the rationality of drug pricing policy and the reimbursement outcome of NHI with payment classified based on the four categories... The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.